Transgenic gene knock-outs: Functional genomics and therapeutic target selection

Pharmacogenomics

Volumn 1, Issue 4, 2000, Pages 433-443

  Harris, Stephen ^a   Foord, Steven M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Deltagen, Inc.; Functional genomics; Gene knock out transgenics; Lexicon Genetics, Inc; Paradigm Therapeutics; Therapeutic target selection

Indexed keywords

ANIMAL; DRUG THERAPY; GENETICS; HUMAN; METHODOLOGY; MUTATION; PHARMACOGENETICS; REVIEW; TRANSGENE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DRUG THERAPY; HUMANS; MUTATION; PHARMACOGENETICS; TRANSGENES;

EID: 0034331075     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.1.4.433     Document Type: Review

References (60)

1. APARICIO SA JR: How to count ... human genes. Nature Genetics (2000) 25:129-130.
2. DREWS J: Genomic sciences and the medicine of tomorrow. Nature Biotechnology (1996) 14:1516-1518. Reviews genomics within the context of the challenges facing the pharmaceutical industry.
3. DREWS J: Drug discovery: a historical perspective. Science (2000) 287:1960-1964.
4. SPENCE P: Genomics: the race is on. Drug Disc. Today (1999) 4:103-104. Introduction to series of relevant articles covering genomics within the issue.
5. DYER MR, COHEN D, HERRLING PL: Functional genomics: from genes to new therapies. Drug Disc. Today (1999) 4:109-114.
6. THOMAS SM: Genomics and intellectual property rights. Drug Disc. Today (1999) 4: 134-138.
7. BEDELL MA, JENKINS NA, COPELAND NG: Mouse models of human disease. Part I: Techniques and resources for genetic analysis in mice. Genes Develop. (1997) 11:1-10. Review of methods available in the mouse.
8. BEDELL MA, LARGAESPADA DA, JENKINS NA, COPELAND NG: Mouse models of human disease. Part II: Recent progress and future directions. Genes Develop. (1997) 11:11-43. Comprehensive review of mouse monogenic disease models, includes potential for modelling polygenic diseases.
9. MOORE K: Utilisation of mouse models in the discovery of human disease genes. Drug Disc. Today (1999) 4:123-128.
10. BATTEY J, JORDAN E, COX D, DOVE W: An action plan for mouse genomics. Nature Genetics (1999) 21:73-75. Commentary on NIH proposals for strengthening mouse genomics and genetics resources.
11. ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD L, FRIEDMAN JM: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372:425-432.
12. TARTAGLIA LA, DEMBSKI M, WENG X et al.: Identification and expression cloning of a leptin receptor, OB-R. Cell (1995) 83:1263-1271.
13. KLEYN PW, FAN W, KOVATS SG et al.: Identification and characterization of the mouse obesity gene tubby: a member of a novel gene family. Cell (1996) 85:281-290.
14. NOBEN-TRAUTH K, NAGGERT JK, NORTH MA, NISHINA PM: A candidate gene for the mouse mutation tubby. Nature (1996) 380:534-538.
15. NAGGERT JK, FRICKER LD, VARLAMOV O et al.: Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nature Genetics (1995) 10:135-142.
16. BULTMAN SJ, MCHAUD EJ, WOYCHIK RP: Molecular characterisation of the mouse agouti locus. Cell (1992) 71:1195-1204.
17. MILLER MW, DUHL DM, VRIELING H et al.: Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev. (1993) 7:454-467.
18. NAGLE DL, MCGRAIL SH, VITALE J et al.: The mahogany protein is a receptor involved in suppression of obesity. Nature (1999) 398:148-152.
19. GUNN TM, MILLER KA, HE L et al.: The mouse mahogany locus encodes a transmembrane form of human attractin. (1999) Nature 398:152-156.
20. DARVESI A: Experimental strategies for the genetic dissection of complex traits in animal models. Nature Genetics (1998) 18:19-24.
21. NADEAU JH, SINGER JB, MATIN A, LANDER ES: Analysing complex genetic traits with chromosome substitution strains. Nature Genetics (2000) 24:221-225. Description of new mouse resources that promise to accelerate QTL mapping of polygenic traits.
22. TALBOT CJ, NICOD A, CHERNY, SS, FULKER DW, COLLINS AC, FLINT J: High-resolution mapping of quantitative trait loci in outbred mice. Nature Genetics (1999) 21:305-308.
23. BALLING R, BROWN SDM, HRABE DE ANGELIS M et al.: Great times for mouse genetics: getting ready for large-scale ENU-mutagenesis. (2000) Mamm. Genome 11:471. Introduction to series of relevant articles within the issue.
24. NOLAN PM, PETERS J, STRIVENS M et al.: A systematic genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nature Genetics (2000) 25:440-443.
25. HRABE DE ANGELIS M, FLASWINKEL H, FUCHS H et al.: Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nature Genetics (2000) 25:444-447.
26. JUSTICE MJ, ZHENG B, WOYCHIK RP, BRADLEY A: Using targeted large deletions and high-efficiency N-ethyl-N-nitrosourea mutagenesis for functional analyses of the mammalian genome. Methods (1997) 13:423-436. Introduction to one method of performing region-specific chemical mutagensis in the mouse.
27. NADEAU JH, FANKEL WN: The roads from phenotypic variation to gene discovery: mutagenesis versus QTLs. Nature Genetics (2000) 25:381-384. Critical retrospective covering the relative merits of the QTL and mutagenesis approaches to gain insight in to in vivo gene function.
28. NADEAU JH: Muta-genetics or muta-genomics: the feasibility of large-scale mutagenesis and phenotyping programs. Mamm. Genome (2000) 11:603-607. Review of gene-based and phenotype-based approaches to defining gene function.
29. CHEN YJ, YEE D, DAINS K et al.: Genotype-based screen for ENU-induced mutations in mouse embryonic stem cells. Nature Genetics (2000) 24:314-317. Proof-of-concept article describing feasibility of chemical mutagenesis via ES cells.
30. MUNROE RJ, BERGSTROM RA, ZHENG QY et al.: Mouse mutants from chemically mutagenized embryonic stem cells. Nature Genetics (2000) 24:318-321. Proof-of-concept article describing feasibility of chemical mutagenesis via ES cell.
31. CHEN Y, SCHIMENTI J, MAGNUSON, T: Toward the yeastification of mouse genetics: chemical mutagenesis of embryonic stem cells. Mamm. Genome (2000) 11:598-602. Review of current status and future prospects for chemical mutagenesis in ES cells.
32. BEIER DR: Sequence-based analysis of mutagenized mice. Mamm. Genome (2000) 11:594-597.
33. PALMITER RD, BRINSTER RL: Germline transformation of mice. Ann. Rev. Genet. (1986) 20:465-499.
34. JAENISCH R: Transgenic animals Science (1988) 240:1468-1474.
35. GORDON JW, RUDDLE FH: Integration and stable germ line transmission of genes injected into mouse pronuclei. Science (1981) 21:1244-1246.
36. HASTY P, ABUIN A, BRADLEY A: Gene targeting, principles and practice in mammalian cells. In: Gene Targeting (2nd Edition): A Practical Approach. Joyner AL (Ed.), Oxford University Press, New York, USA (2000):1-35.
37. SURAOKAR M, BRADLEY A: Genetics. Targeting sheep. Nature (2000) 405:1004-1005.
38. COLMAN A: Somatic cell nuclear transfer in mammals: Progress and applications. Cloning (2000) 1:185-200.
39. MCCREATH KJ, HOWCROFT J, CAMPBELL KHS, COLMAN A, SCHNIEKE AE, KIND AJ: Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature (2000) 405:1066-1069. Proof-of-concept article describing the first targeted manipulation of a genome in a species other than the mouse.
40. LOBE CG, NAGY A: Conditional genome alteration in mice. Bioessays (1998) 20:200-208.
41. DEAN SW, BROOKS TM, BURLINSON B et al.: Transgenic mouse mutation assay systems can play an important role in regulatory mutagcnicity testing in vivo for the detection of site-of-contact mutagens. (1999) Mutagenesis 14:141-151. Review of transgenic utility in candidate drug selection phase of drug discovery.
42. STORER RD: Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals - scientific perspective. Toxicol. Letts. (2000) 112-113:557-566. Review of status of transgenic models in candidate drug selection phase of drug discovery.
43. CATERINA MJ, LEFFLER A, MALMBERG AB et al.: Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science (2000) 288:306-313.
44. DAVIS JB. GRAY J, GUNTHORPE MJ et al.: Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature (2000) 405:183-187.
45. KIEFFER BL: Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. (1999) 20:19-26. Review of early biological and pharmacological insights obtained by comparing available opioid receptor gene knock-outs for members of this tractable gene family.
46. KABLE JW, MURRIN LC, BYLUND DB: In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J. Pharmacol. Exp. Ther. (2000)293:1-7. Review of biological insight in to gene function obtained for members of a tractable gene family using comparative transgenics, including gene knock-outs.
47. HUSZAR D, LYNCH CA, FAIRCHILD-HUNTRESS V et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell (1997) 88:131-141.
48. CHEN W, KELLY MA, OPITZ-ARAYA X, THOMAS RE, LOW MJ, CONE RD: Exocrine gland dysfunction in MC5-R-deficient mice: evidence for co-ordinated regulation of exocrine gland function by melanocortin peptides. Cell. (1997) 91:789-798.
49. ROHRER DK, KOBILKA BK: G protein-coupled receptors: functional and mechanistic insights through altered gene expression. Physiol. Rev. (1998) 78:35-52.
50. SMITH A: Pass the protease: new interactions between GPCRs. Trends Pharmacol. Sci. (2000) 21:291.
51. ROSSI D, ZLOTNIK A: The biology of chemokines and their receptors. Ann. Rev. Immunol. (2000) 18:217-242.
52. 4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. Neuroscience (1999) 19:9550-9556.
53. SUGIMOTO Y, NARUMIYA S, ICHIKAWA A: Distribution and function of prostanoid receptors: studies from knockout mice. Prog. Lipid Res. (2000) 39:289-314.
54. OHISHI S, UENO A, MATSUMOTO H, MURATA T, USHIKUBI F, NARUMIYA S: Evidence for involvement of prostaglandin I2 as a major nociceptive mediator in acetic acid-induced writhing reaction: a study using IP-receptor disrupted mice. Adv. Exp. Med. Biol. (1999) 469:265-268.
55. WALTHER T, BALSCHUN D, VOIGT JP, FINK H, ZUSCHRATTER W, BIRCHMEIER C et al.: Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem. (1998) 273:11867-11873.
56. BLEASE K, MEHRAD B, STANDIFORD TJ et al.: Enhanced pulmonary allergic responses to Aspergillus in CCR2-/- mice. J. Immunol. (2000) 165:2603-2611.
57. LUCAS JJ, HEN R: New players in the 5-HT receptor field - genes and knockouts. Trends Pharmacol. Sci. (1995) 16:246-252.
58. ZAMBROWICZ BP, FRIEDRICH GA, BUXTON EC, LILLEBERG SL, PERSON C, SANDS AT: Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature (1998) 392:608-611.
59. http://www.lexicon-genetics.com/home.html Lexicon Genetics, Inc. (2000).
60. http://wwsv.deltagen.com/ Deltagen, Inc. (2000).